logo image
☰ search icon
Idiopathic Pulmonary Fibrosis Management Market

Idiopathic Pulmonary Fibrosis Management Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib, Interferon Gammato1b, Others), By Treatment (Oxygen Therapy, Lung Transplant), By Route of Administration, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region, And By Segment Forecasts, 2024-2031

Report ID : 2885 | Published : 2024-11-12 | Pages: 165 | Format: PDF/EXCEL

Share

The Idiopathic Pulmonary Fibrosis Management Market Size is valued at USD 3,113.5 Mn in 2023 and is predicted to reach USD 3,429.6 Mn by the year 2031 at a 1.28% CAGR during the forecast period for 2024-2031.

fibrosis management

Idiopathic Pulmonary Fibrosis Management is referred to as a serious disease related to the lungs, which stiffens, thickens, and damages the lung tissues over a prolonged period. Hence, the adoption of idiopathic pulmonary fibrosis management is expected to increase in the near future as concerns grow over people's health. The growing prevalence of Idiopathic Pulmonary Fibrosis in middle-aged men is a factor expected to drive the development of the global Idiopathic Pulmonary Fibrosis Management market. The availability of several treatments and the adoption of newly advanced technology are some of the other factors estimated to augment the target market growth. The rapid advancements in research and drug innovations globally are expected to push the market expansion in the coming years.

However, The high cost of Idiopathic Pulmonary Fibrosis Management, lack of treatment, and COVID-19 outbreak may hinder target market expansion over the forecast period. Enhanced R&D, government initiatives promoting sustainable production components, and investments from leading entities are expected to generate significant revenue growth opportunities for global Idiopathic Pulmonary Fibrosis Management market participants during the forecast period.

Competitive Landscape

Some Major Key Players In The Idiopathic Pulmonary Fibrosis Management Market:

  • Avalyn Pharma, Inc.,
  • Hoffmann-La. Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Medicinova, Inc.
  • Merck & Co., Inc.
  • Galapagos NV
  • Novartis AG
  • Fiberogen, Inc.
  • Biogen
  • Novartis AG
  • Blade Therapeutics
  • Neopharm Group
  • Galecto Biotech
  • Pfizer Inc
  • Johnson & Johnson Services, Inc
  • AstraZeneca
  • Daewoong Pharmaceutical (India) Pvt Ltd,
  • Sandoz International GmbH (Novartis)
  • Algernon Pharmaceuticals Inc.
  • Genentech, Inc.
  • Other Market Players

Market Segmentation:

The Idiopathic Pulmonary Fibrosis Management market is segmented based on drug class, route of administration, and distribution channel. The drug class segment comprises pirfenidone, nintedanib, interferon gammato1b, and others. According to the route of administration, the segmention includes oral, injectable, and others. The distribution channel segment includes hospital pharmacies, retail pharmacies, and others.

Based On Drug Class, The Pirfenidone Segment Accounts For A Major Contributor To The Idiopathic Pulmonary Fibrosis Management Market.

The pirfenidone category is expected to hold a major share of the global Idiopathic Pulmonary Fibrosis Management market in 2023. This is attributed to providing a unique combination of anti-fibrotic, antioxidant, and anti-inflammatory properties. Additionally, its efficiency is proven in clinical trials and continuous research and development initiatives, which are rapidly raising its value and attractiveness to the healthcare sector.

The Hospital Pharmacies Segment Witnessed A Rapid Growth.

The hospital pharmacies projected to grow at a rapid rate in the global Idiopathic Pulmonary Fibrosis Management market owing to its advanced diagnostic tools. Additionally, hospital pharmacies offer expert guidance on medication use and administration, ensuring optimal patient care in the rising prevalence of  Idiopathic Pulmonary Fibrosis Management in hospital pharmacies.

In The Region, The North America Idiopathic Pulmonary Fibrosis Management Market Holds A Significant Revenue Share.

The North American idiopathic Pulmonary Fibrosis Management market is expected to register the highest market revenue share in the comming future. This can be attributed to the strong focus on lung patients in the region, with the increasing adoption of Idiopathic Pulmonary Fibrosis Management. In addition, the advanced properties in healthcare infrastructure, specialized IPF diagnosis, well-equipped infrastructure, and providing timely and effective treatment. Growing research and development, as well as improved access to approved therapies for idiopathic pulmonary fibrosis management in the production of intermediate chemicals in the region, are factors increase the growth of the target market in the region. Also, Asia Pacific region is projected to show rapid growth in the global Idiopathic Pulmonary Fibrosis Management market due to growing pharmaceutical innovations, rising demand for effective treatment, rapid industrialization, government initiatives, and increasing funding in various industries.

Recent Developments:

  • In Oct 2024, Novartis has discontinued a phase 2 trial of its SMURF1 inhibitor LTP001 for idiopathic pulmonary fibrosis (IPF) but will proceed with the development of the candidate for a different indication. The Swiss pharmaceutical company ceased patient enrollment in the experiment early this year, despite having reached only half of its target, but continued to monitor the 46 individuals already participating in the study.
  • In September 2024, Boehringer Ingelheim released that its FIBRONEER-IPF research on nerandomilast had effectively reached its primary aim and encouraged preparations for a new medication application for the treatment of IPF.

Idiopathic Pulmonary Fibrosis Management Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 3,113.5 Mn

Revenue Forecast In 2031

USD 3,429.6 Mn

Growth Rate CAGR

CAGR of 1.28% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Drug Class, Treatment, Route Of Administration, And Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Avalyn Pharma, Inc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Medicinova, Inc., Merck & Co., Inc., Galapagos NV, Novartis AG, Fiberogen, Inc., Biogen, Blade Therapeutics, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc., AstraZeneca, Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), Algernon Pharmaceuticals Inc., and Genentech, Inc.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1.       Methodology and Scope

1.1.      Research Methodology

1.2.      Research Scope & Assumptions

Chapter 2.       Executive Summary

Chapter 3.       Global Idiopathic Pulmonary Fibrosis Management Market Snapshot

Chapter 4.       Global Idiopathic Pulmonary Fibrosis Management Market Variables, Trends & Scope

4.1.      Market Segmentation & Scope

4.2.      Drivers

4.3.      Challenges

4.4.      Trends

4.5.      Investment and Funding Analysis

4.6.      Porter's Five Forces Analysis

4.7.      Incremental Opportunity Analysis (US$ MN), 2024-2031

4.8.      Global Idiopathic Pulmonary Fibrosis Management Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031

4.9.      Competitive Landscape & Market Share Analysis, By Key Player (2023)

4.10.    Use/impact of AI on Idiopathic Pulmonary Fibrosis Management Industry Trends

Chapter 5.       Idiopathic Pulmonary Fibrosis Management Market Segmentation 1: By Drug Class, Estimates & Trend Analysis

5.1.      Market Share by Drug Class, 2023 & 2031

5.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:

5.2.1.   Pirfenidone

5.2.2.   Nintedanib

5.2.3.   Interferon Gammato1b

5.2.4.   Others

Chapter 6.       Idiopathic Pulmonary Fibrosis Management Market Segmentation 2: By Treatment, Estimates & Trend Analysis

6.1.      Market Share by Treatment, 2023 & 2031

6.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatments:

6.2.1.   Oxygen Therapy

6.2.2.   Lung Transplant

6.2.3.   Others

Chapter 7.       Idiopathic Pulmonary Fibrosis Management Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis

7.1.      Market Share by Route of Administration, 2023 & 2031

7.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:

7.2.1.   Oral

7.2.2.   Injectable

Chapter 8.       Idiopathic Pulmonary Fibrosis Management Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis

8.1.      Market Share by Distribution Channel, 2023 & 2031

8.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:

8.2.1.   Hospital Pharmacies

8.2.2.   Retail Pharmacies

8.2.3.   Online Pharmacies

Chapter 9.       Idiopathic Pulmonary Fibrosis Management Market Segmentation 5: Regional Estimates & Trend Analysis

9.1.      Global Idiopathic Pulmonary Fibrosis Management Market, Regional Snapshot 2023 & 2031

9.2.      North America

9.2.1.   North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

9.2.1.1.            US

9.2.1.2.            Canada

9.2.2.   North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031

9.2.3.   North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031

9.2.4.   North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

9.2.5.   North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

9.3.      Europe

9.3.1.   Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

9.3.1.1.            Germany

9.3.1.2.            U.K.

9.3.1.3.            France

9.3.1.4.            Italy

9.3.1.5.            Spain

9.3.1.6.            Rest of Europe

9.3.2.   Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031

9.3.3.   Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031

9.3.4.   Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

9.3.5.   Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

9.4.      Asia Pacific

9.4.1.   Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

9.4.1.1.            India

9.4.1.2.            China

9.4.1.3.            Japan

9.4.1.4.            Australia

9.4.1.5.            South Korea

9.4.1.6.            Hong Kong

9.4.1.7.            Southeast Asia

9.4.1.8.            Rest of Asia Pacific

9.4.2.   Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031

9.4.3.   Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031

9.4.4.   Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031

9.4.5.   Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

9.5.      Latin America

9.5.1.   Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

9.5.1.1.            Brazil

9.5.1.2.            Mexico

9.5.1.3.            Rest of Latin America

9.5.2.   Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031

9.5.3.   Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031

9.5.4.   Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

9.5.5.   Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

9.6.      Middle East & Africa

9.6.1.   Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

9.6.1.1.            GCC Countries

9.6.1.2.            Israel

9.6.1.3.            South Africa

9.6.1.4.            Rest of Middle East and Africa

9.6.2.   Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031

9.6.3.   Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031

9.6.4.   Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

9.6.5.   Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

Chapter 10.     Competitive Landscape

10.1.    Major Mergers and Acquisitions/Strategic Alliances

10.2.    Company Profiles

 

10.2.1. Boehringer Ingelheim GMBH

10.2.1.1.          Business Overview

10.2.1.2.          Key Product/Service Offerings

10.2.1.3.          Financial Performance

10.2.1.4.          Geographical Presence

10.2.1.5.          Recent Developments with Business Strategy

10.2.2. Biogen

10.2.3. Novartis AG

10.2.4. Medicinova Inc

10.2.5. Bristol Myers Squibb Company

10.2.6. Galapagos NV

10.2.7. Hoffmann-La Roche AG

10.2.8. Neopharm Group

10.2.9. Galecto Biotech

10.2.10.           Pfizer Inc

10.2.11.           Johnson & Johnson Services, Inc

10.2.12.           AstraZeneca

10.2.13.           Other Prominent Players

Segmentation of Idiopathic Pulmonary Fibrosis Management Market-

Idiopathic Pulmonary Fibrosis Management Market By Product-

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato 1b
  • Others

Idiopathic Pulmonary Fibrosis Management Market By Route of Administration-

  • Oral
  • Injectable

Idiopathic Pulmonary Fibrosis Management Market By Treatment-

  • Oxygen Therapy
  • Lung Transplant
  • Others

 fibrosis management

Idiopathic Pulmonary Fibrosis Management Market By Distribution Channel-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Idiopathic Pulmonary Fibrosis Management Market Size?

The Idiopathic Pulmonary Fibrosis Management Market is expected to grow at a 1.28% CAGR during the forecast period for 2024-2031.

Avalyn Pharma, Inc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Medicinova, Inc., Merck & Co., I

Drug Class, Treatment, Route Of Administration, And Distribution Channel are the key segments of the Idiopathic Pulmonary Fibrosis Management Market.

North American region is leading the Idiopathic Pulmonary Fibrosis Management Market.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach
Related Reports
logo

Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.

  • facebook icon
  • twitter icon
  • linkedin icon
Category
Quick Links
Office Address